Research: Weight loss drugs can also reduce the risk of Alzheimer's.
Recently, a large-scale study on popular weight loss drugs showed that patients using GLP-1 medications (such as Novo-Nordisk A/S's Ozempic and Wegovy, and Eli Lilly and Co's Mounjaro) had a 12% reduced risk of developing Alzheimer's disease, but there was an increase in the risk of arthritis, kidney, and pancreatic diseases.
NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts
LVMH Is Once Again the Largest Company in Europe by Market Cap
Why Did Novo Nordisk (NVO) Go Down on Friday?
Trending Stocks as Wall Street Bounces Back With Strong Week
Top Gap Ups and Downs on Friday: NVO, UBS, IBN and More
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
